Found 36 articles
Sorrento Announces License From Columbia University For Rapid On-Site Detection Test For SARS-CoV-2 Virus In Saliva
-- Test gives simple positive or negative color change results in 30 minutes or less -- No special laboratory equipment required, hence practical for on-site deployment -- Test uses saliva, eliminating need for painful nasal swabbing -- Study shows sensitivity and specificity of 97% and 100%, respectively
Sorrento Enters Into Letter Of Intent To Acquire SmartPharm And Develop Pipeline Of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies To Treat COVID-19 and Cancer Therapeutics
-- The combination of SmartPharm's Gene Mab™ gene-encoded in vivo expression system and Sorrento's SARS-CoV-2 neutralizing antibodies may potentially provide longer-acting, single injection protection against COVID-19. -- The combination of Sorrento's proprietary fully human G-MAB™ Antibody Library and SmartPharm's Gene-Encoded Therapeutics (GET) Platform is expected to provide a vast product pipeline of novel, long-acting therapeutic proteins for treating a broad range of diseases, in
FDA clears Abivertinib for Phase 2 safety and efficacy study in hospitalized patients with moderate to severe COVID-19
- Abivertinib is a novel Tyrosine Kinase Inhibitor with dual selective targeting of mutant forms of EGFR and BTK that has completed a registration trial (lung cancer) and been administered to over 600 patients worldwide. - The compound demonstrated in-vitro the ability to simultaneously lower multiple critical inflammatory cytokines associated with cytokine storm and poor prognosis in COVID-19 patients. - It is to be tested next in a Phase 2 trial in moderate to severe COVID-
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has published a pre-print publication (https://www.biorxiv.org/content/10.1101/2020.06.29.178616v1.full.pdf) describing initial pre-clinical results from its COVID-19 vaccination program, which introduced a novel targeted protein vaccine against COVID-19, referred to as T-VIVA-19.
Sorrento Therapeutics, Inc. announced that it prepaid in full its outstanding term loans on June 12, 2020.
In an interview, Lilly's CSO said the third antibody could possibly begin human trials in the new few weeks. But the statement that got everyone more excited was when he indicated one of the antibodies might be available for use by September.
Sorrento Announces It Has Submitted an Emergency Use Authorization (EUA) Application for the COVI-TRACK Diagnostic Test for the Detection of Antibodies to SARS-CoV-2
Sorrento Therapeutics, Inc. announced that an Application for Emergency Use Authorization is under review at the U.S. Food and Drug Administration for its COVI-TRACKTMin vitro diagnostic test kit for the independent detection of IgG and IgM antibodies in sera of patients exposed to the SARS-CoV-2 virus.
Sorrento COVIDTRAP™(STI-4398) Demonstrates in Preclinical Studies its Ability to Completely Inhibit SARS-CoV-2 Viral Infection In Vitro
- COVIDTRAPTM, a proprietary ACE2-Fc decoy protein, binds strongly to the spike protein of the SARS-CoV-2 virus; - COVIDTRAP neutralizes the SARS-CoV-2 virus and prevents infection in African green monkey kidney epithelial cells (VERO/E6 cells) in vitro at low concentration; - STI-4398 has received FDA Feedback on the rapid development of the product candidate; and - Together with Sorrento's previously announced potent STI-1499 neutralizing antibody preclinical prod
Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for STI-6129, a CD38-targeting antibody drug conjugate (ADC). STI-6129 utilizes several technology platforms that are under development by Sorrento Therapeutics, including a CD38 specific antibody identified from its fully human G-MAB™ antibody library, its
Henry Li, Sorrento's co-founder, director, president and chief executive officer, did a follow-up interview with BioSpace to discuss the news and speculation surrounding it.
Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTK More than 600 patients have been treated with the compound across studies, with over 200 patients in the completed registrational trial SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) have entered into a binding term sheet for an exclusive license to ACEA’s Abivertinib across all indications for all territories outside of C
The company announced that one of its antibodies, STI-1499, has shown 100% inhibition of SARS-CoV-2 in laboratory tests.
STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration.
The partnership is aimed at creating antibody products that could act as a “protective shield” against infection by the virus that causes COVID-19, SARS-CoV-2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
Sorrento And Mount Sinai Health System To Jointly Develop COVI-SHIELD™ Antibody Therapy Targeting SARS-CoV-2 Infection (COVID-19)
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and Mount Sinai Health System (" Mount Sinai ") have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD™) to potentially treat COVID-19.